GO
Loading...

Medicine

More

  • Nov 19- Synergy Pharmaceuticals Inc said its experimental drug for opioid-induced constipation was found safe and effective in a mid-stage trial. Synergy Pharmaceuticals shares were up 8 percent in premarket trading. The drug SP-333 showed statistically significant improvement in spontaneous bowel movement in the fourth week of treatment, compared...

  • Nov 19- Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash. Vertex's cystic fibrosis drug, Kalydeco, was approved by the U.S. Food and Drug Administration in January 2012. Vertex co-developed the drug with an affiliate...

  • Study will test survivors' blood to treat Ebola Tuesday, 18 Nov 2014 | 10:02 PM ET

    The Bill& Melinda Gates Foundation is giving $5.7 million to scale up production of the treatments for the project in Guinea and other Ebola-affected countries in Africa. Besides helping Ebola patients now, plasma "could be a tool for a future epidemic as well" from different viruses, Microsoft co-founder Bill Gates said in an interview with The Associated...

  • Trading 3-D: Pro loves HPQ     Tuesday, 18 Nov 2014 | 5:17 PM ET

    The "Fast Money" traders dig into the play on 3-D printing companies Hewlett-Packard and Organovo.

  • *AstraZeneca designates oncology as new growth driver. LONDON, Nov 18- AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs on Tuesday, aiming to show investors it has a strong independent future just days before takeover rules would allow Pfizer to launch a new bid. AstraZeneca, which saw off a $118 billion approach from Pfizer in May, is his...

  • LONDON, Nov 18- Here are some key facts about avian influenza, after cases of H5N8 bird flu were detected on farms in Germany and the Netherlands:. The World Organisation for Animal Health says animal feed can be another factor in transmission of the disease-- if wild birds and others have access to the same feed-- as well as equipment and clothing.

  • Nov 18- CytRx Corp said the U.S. Food and Drug Administration placed a hold on enrolling new patients in clinical trials of its experimental cancer drug after a patient died, sending the company's shares down 11 percent in premarket trading. Patients already enrolled in the trials, currently in mid stage, will continue receiving the treatment, CytRx said.

  • *AstraZeneca designates oncology as new growth driver. LONDON, Nov 18- AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs at an investor day on Tuesday, aiming to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May. AstraZeneca is his biggest holding.

  • CHICAGO, Nov 17- An experimental heart failure medicine from Novartis that previously showed it reduced death and hospitalizations also curtailed worsening of symptoms, need for additional therapy and emergency room visits, adding to evidence that it will become the drug of choice once approved. The Novartis drug, expected to become a multibillion-dollar...

  • Outbreaks like Ebola will happen again: NIH Monday, 17 Nov 2014 | 3:57 PM ET
    File photo: A young man, dressed in a biohazard costume, stands on the corner of 546 West 147th Street in October 2014 in New York City after an American doctor carrying the ebola virus was admitted to Bellevue Hospital

    NIH's Dr. Francis Collins and Milken Institute Chairman Mike Milken make the case for medical research funding to stop outbreaks like Ebola.

  • Advances in medical research     Monday, 17 Nov 2014 | 2:13 PM ET

    Discussing research funding for diseases, as well as Ebola, with Michael Milken, Milken Institute Chair, and Dr. Francis Collins, NIH director.

  • CHICAGO, Nov 17- After years of uncertainty, a nearly decade-long study showed that Merck& Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin. Christopher Cannon, lead investigator of the 18,144- patient Improve-It study presented at the American Heart Association...

  • CHICAGO, Nov 17- Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck& Co's Zetia, according to data from a clinical trial presented on Monday. Alirocumab, developed along with French drugmaker Sanofi, belongs to a new...

  • Ebola continues to rage in West Africa     Monday, 17 Nov 2014 | 10:09 AM ET

    Ebola patient Dr. Martin Salia has died from the virus. CNBC's Meg Tirrell discusses the need for better and faster Ebola diagnostics.

  • Study lifts cloud over heart drugs Zetia, Vytorin Monday, 17 Nov 2014 | 8:53 AM ET

    CHICAGO— A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. Merck& Co.' s ezetimibe, which went on sale in 2002, lowers cholesterol in a different way. The drug won Food and Drug Administration approval for lowering LDL, but some studies suggested that might not translate to fewer heart attacks and strokes.

  • LONDON, Nov 17- An experimental lupus drug from AstraZeneca significantly improved the symptoms of lupus in a mid-stage clinical trial, boosting prospects for a medicine the company believes could become a major seller. AstraZeneca's sifalimumab works in a different way to Benlysta by targeting interferon, a protein involved in inflammation.

  • British, Dutch kill poultry to fight bird flu Monday, 17 Nov 2014 | 4:51 AM ET

    LONDON— Chickens were being killed in the Netherlands, and Britain was preparing to kill ducks, after two cases of bird flu were discovered in Europe— but officials insisted Monday that the risk to public health was very low. The U.K. government food agency said there is no risk to the food chain and British Chief Veterinary Officer Nigel Gibbens told BBC the risk of...

  • Heart stents may require longer blood thinner use Sunday, 16 Nov 2014 | 4:47 PM ET

    Patrick O'Gara, clinical cardiology chief at Brigham and Women's Hospital in Boston and president of the American College of Cardiology. Laura Mauri, at the request of the federal Food and Drug Administration. Results were discussed Sunday at an American Heart Association conference in Chicago and published online by the New England Journal of Medicine.

  • Nov 16- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead...

  • FDA approves Lemtrada for multiple sclerosis Saturday, 15 Nov 2014 | 1:00 PM ET

    NEW YORK— The Food and Drug Administration has approved Lemtrada, a treatment for relapsing multiple sclerosis made by the drugmaker Genzyme. Sanofi, the parent company of Genzyme, wants to market Lemtrada as a treatment for relapsing multiple sclerosis, a disease in which the immune system attacks healthy nerves. Sanofi estimates that the disease affects...